MEPROBAMATE
LOE ApproachingNDAORALTABLET
Approved
Jul 1963
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
MEPROBAMATE by Novartis is clinical pharmacology meprobamate is a carbamate derivative which has been shown in animal studies to have effects at multiple sites in the central nervous system including the thalamus and limbic system. Approved for anxiety disorders, for the short-term relief of the symptoms of anxiety. First approved in 1963.
Drug data last refreshed 2h ago · AI intelligence enriched 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Meprobamate is an oral carbamate derivative small molecule approved in 1963 for short-term relief of anxiety disorders. It works by exerting effects at multiple CNS sites including the thalamus and limbic system. This is a legacy anxiolytic with decades of clinical use but declining relevance in modern psychiatry.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100); legacy brand team likely focused on defensive positioning and generic transition management.
Mechanism of Action
CLINICAL PHARMACOLOGY Meprobamate is a carbamate derivative which has been shown in animal studies to have effects at multiple sites in the central nervous system including the thalamus and limbic system.
Worked on MEPROBAMATE at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.